In the Industry

At Lyra, we are advancing leading-edge science to develop therapeutics that can make a positive impact on the lives of millions of patients.

Here are some of the ways we are making a difference for patients, for new therapeutic products, and for our community.

October 4, 2021
LYR-210 Phase 2 data selected for ARS Clinical Science Maurice Cottle Award

Lyra’s LYR-210 Phase 2 data was selected to receive the Clinical Science Maurice Cottle Award honoring best clinical or basic science, named after the founder of the American Rhinologic Society, announced at the ARS Annual Meeting in Los Angeles on Saturday, October 1st.

October 4, 2021
At ARS: Lyra presents new positive Phase 2 LANTERN 6-month follow-up and LYR-210 pharmacokinetic data

New, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society (ARS), October 2021, with the PK study selected as a top clinical abstract at the meeting.

September 17, 2021
Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Published in the International Forum of Allergy & Rhinology (IFAR): positive data from our LANTERN Ph2 study with LYR-210, in development as a non-invasive alternative to sinus surgery for patients with chronic rhinosinusitis.

June 16, 2021
Lyra CEO Maria Palasis named Extraordinary Women Advancing Healthcare 2021 winner

Lyra CEO Maria Palasis was named an Extraordinary Women Advancing Healthcare 2021 winner by The Commonwealth Institute, honoring remarkable leaders shaping healthcare across Massachusetts.

June 3, 2021
Lyra CEO Maria Palasis named to 2021 Medical Marketing & Media Hall of Femme

Lyra CEO Maria Palasis was recognized as part of the 2021 Medical Marketing & Media Hall of Femme, highlighting standout woman healthcare executives in biopharma, med device/diagnostics, marketing/communications and media.

April 11, 2021
Lyra presents positive LANTERN Phase 2 study results for LYR-210 in chronic rhinosinusitis (CRS) at COSM

Lyra CMO Robert Kern, MD, discusses the positive LANTERN Phase 2 study results for LYR-210, offering hope for a new treatment option with up to 6 months of relief for Chronic Rhinosinusitis patients.

March 19, 2021
How Lyra Therapeutics is Advancing Rhinosinusitis Treatment

Drug Delivery Business took a dive into Lyra’s product approach for chronic rhinosinusitis, LYR-210 and the company’s platform for ENT and other chronic diseases.

February 25, 2021
Lyra named as one of “8 Drug Delivery Innovations You Need to Know”

On the MassDevice list of “8 drug delivery innovations you need to know,” Lyra was recognized as “looking to make waves in the ear, nose and throat (otolaryngology) disease treatment space with drugs administered through a bioresorbable polymeric matrix.”

February 17, 2021
Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer

We are pleased to welcome our new CMO, Robert Kern, MD, a renowned physician in the ENT field and a world-leading expert in chronic rhinosinusitis. Introduced in this Drug Delivery Business News article, Dr. Kern will oversee the development of Lyra’s clinical pipeline.

February 10, 2021
Lyra CEO Maria Palasis elected into the National Academy of Engineering

Lyra CEO Maria Palasis was elected into the National Academy of Engineering for outstanding contributions to the design of medical devices and drug delivery systems, including her work on LYR-210 and LYR-220.

November 10, 2020
MedExec Women Fall Forum: CEO Maria Palasis hosts networking sessions

Lyra CEO Maria Palasis hosted two networking sessions on Combination Products at the MedExecWomen Fall Forum, focused on advances in medtech and medical devices by women leaders.

October 28, 2020
Lyra Therapeutics Appoints Nancy L. Snyderman to Board of Directors

Lyra is pleased to welcome Dr. Nancy Snyderman to the Board of Directors. An accomplished otolaryngologist and surgeon, she brings deep expertise that will be invaluable as we advance innovative treatments for ear, nose and throat diseases.

July 14, 2020
Diversity Interview Series: CEO Maria Palasis shares advice on gender diversity

How can companies add more women in leadership roles? How can women pursue these positions? In a Q&A, CEO Maria Palasis discusses specific steps both can take to increase gender diversity in the workplace.

June 18, 2020
CEO Maria Palasis discusses how Lyra completed its IPO during the COVID-19 pandemic on a life sciences panel

Lyra CEO Maria Palasis was one of three women leaders in life sciences discussing the current unique capital raising environment on a panel hosted by BioDirector.

May 6, 2020
Lyra rings Nasdaq opening bell

The Lyra team participated in the Nasdaq virtual opening bell ringing ceremony to commemorate the company’s first week on the Nasdaq exchange as LYRA.

Back to Top